HIV/AIDS

Risk for Secondary Tumors After Kaposi Sarcoma Has Changed in the HAART Era

Risk for Secondary Tumors After Kaposi Sarcoma Has Changed in the HAART Era

By

Tumors, such as acute lymphocytic leukemia, cancer of the tongue, and cancer of the penis, are becoming more common in the HAART era compared with the pre-HAART era.

HIV Risk Behaviors More Prominent in Women With Mental Disorders

HIV Risk Behaviors More Prominent in Women With Mental Disorders

By

Women with a mental disorder, specifically characteristics of antisocial personality disorder and borderline personality disorder, are more sexually active than their male counterparts.

Once-Daily Single-Tablet HIV Treatment Safe, Effective in Children

Once-Daily Single-Tablet HIV Treatment Safe, Effective in Children

By

The single tablet regimen is a combination of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide.

New Single-Tablet Treatment for HIV Infection Advantageous to Standard Therapy

New Single-Tablet Treatment for HIV Infection Advantageous to Standard Therapy

By

Virological response, efficacy, noninferiority, and tolerability were tested for bictegravir, emtricitabine, and tenofovir alafenamide vs dolutegravir, abacavir, and lamivudine.

 Single Measure Viral Load Estimates of HIV Suppression in 2014

Single Measure Viral Load Estimates of HIV Suppression in 2014

Single measures of viral load can overestimate how many individuals with HIV infection have viral suppression.

Hepatitis B, Hepatitis C, HIV More Common in Severe Mental Illness

Hepatitis B, Hepatitis C, HIV More Common in Severe Mental Illness

By

HIV, hepatitis B, and hepatitis C infections are more prevalent among patients with severe mental illness than in the general population.

Bone Loss and Fracture Risk in Patients With HIV: What We Know So Far

Bone Loss and Fracture Risk in Patients With HIV: What We Know So Far

By

In addition to prevention measures, switching off the ARTs associated with bone loss and administering intravenous bisphosphonate, a bone resorption inhibitor, can be an effective strategy for preventing bone loss seen in HIV-infected individuals.

Point-of-Care Tests for HIV and T pallidum Infections: Utility of Smartphone-Based Electronic Reader

Point-of-Care Tests for HIV and T pallidum Infections: Utility of Smartphone-Based Electronic Reader

By

A smartphone-based electronic reader with dual point of care tests were evaluated in the detection of antibodies to T pallidum and HIV.

Offering Rapid HIV Testing in EDs Increase Testing Rates

Offering Rapid HIV Testing in EDs Increase Testing Rates

By

Rapid HIV testing offered to patients in addition to a clinician consultation increases the testing rate in the emergency department.

Viral Load Rebound Seen After HIV Suppression in Pregnancy

Viral Load Rebound Seen After HIV Suppression in Pregnancy

Women achieving HIV viral suppression in pregnancy can experience viral load rebound predelivery.

FDA Expands Epclusa® Indication for HCV/HIV Co-infection

FDA Expands Epclusa® Indication for HCV/HIV Co-infection

By

The FDA has approved an expanded indication for Epclusa to include the use of this once-daily single tablet regimen in patients co-infected with chronic hepatitis C virus and HIV.

Aging With HIV: Expert Insights on Complications and Challenges

Aging With HIV: Expert Insights on Complications and Challenges

By

Three HIV experts provide their insights into aging-related challenges and complications faced by people living with HIV.

HIV Status May Not Effect Incidence of Invasive Cervical Cancer

HIV Status May Not Effect Incidence of Invasive Cervical Cancer

By

HIV infection may not contribute to incidence of invasive cervical cancer.

FDA Grants Priority Review to Single Tablet HIV Regimen

FDA Grants Priority Review to Single Tablet HIV Regimen

By

The FDA has granted Priority Review to the New Drug Application for Gilead's investigational single-tablet regimen in the treatment of HIV-1 infection.

Penile Microbiome Linked to Increased HIV Risk in Heterosexual Partners

Penile Microbiome Linked to Increased HIV Risk in Heterosexual Partners

The microbiome of the area on the penis located under the foreskin in uncircumcised straight men has been linked to increased risk for contracting HIV.

Antiretroviral Therapy Associated With Decreases in Bone Mineral Density

Antiretroviral Therapy Associated With Decreases in Bone Mineral Density

By

Patients with HIV undergoing antiretroviral therapy saw significant decreases in bone mineral density.

Bone Density at the Hip Declines Twice as Fast in HIV-Infected Women

Bone Density at the Hip Declines Twice as Fast in HIV-Infected Women

By

Femoral neck bone mineral density declines twice as fast in HIV-infected women vs HIV-infected men.

Walgreens Expands HIV PrEP Availibility

Walgreens Expands HIV PrEP Availibility

By

Providers at Walgreens Healthcare Clinics in 17 new locations will be able to prescribe PrEP for HIV prevention.

CDC: No Evidence to Encourage More Frequent HIV Screening in MSM

CDC: No Evidence to Encourage More Frequent HIV Screening in MSM

By

The CDC systematic review follows a trend of clinicians offering more frequent HIV screening to gay, bisexual, and other men who have sex with men, but the evidence is insufficient to warrant a change to the current recommendations.

New Genvoya Label Includes Safety, Efficacy, Resistance, Drug Interactions

New Genvoya Label Includes Safety, Efficacy, Resistance, Drug Interactions

By

The FDA has approved labeling changes for Genvoya to include long-term efficacy, safety, resistance data and drug interactions.

WHO Urges for Action Plan to Tackle HIV Drug Resistance

WHO Urges for Action Plan to Tackle HIV Drug Resistance

By

The WHO has alerted countries to take action against the growing threat of HIV drug resistance.

Mortality Improves With Enhanced Prophylaxis and ART in Advanced HIV

Mortality Improves With Enhanced Prophylaxis and ART in Advanced HIV

For patients with advanced HIV who are initiating antiretroviral therapy, enhanced prophylaxis is associated with reduced rates of death.

Point-of-Care Testing of HIV-Exposed Infants Improves Linkage to Care

Point-of-Care Testing of HIV-Exposed Infants Improves Linkage to Care

By

Point-of-care testing of HIV-exposed infants at birth yielded results comparable to the standard of care laboratory-based testing and reduced time to result and time to antiretroviral therapy initiation.

Amphotericin and Flucytosine Safe, Effective for HIV-Associated Cryptococcal Meningitis

Amphotericin and Flucytosine Safe, Effective for HIV-Associated Cryptococcal Meningitis

By

One-week amphotericin plus flucytosine was found to have comparable efficacy and safety profiles as the standard of care, 2-weeks amphotericin-based therapy, for treatment of HIV-associated cryptococcal meningitis in African patients.

Better Diagnostics Needed for Milder HIV-Associated Neurocognitive Disorders

Better Diagnostics Needed for Milder HIV-Associated Neurocognitive Disorders

By

In order to assess and manage milder forms of HIV-associated neurocognitive disorders, effective cognitive screening instruments are needed.

Efficacy of Crofelemer in Chronic HIV-Related Diarrhea Evaluated

Efficacy of Crofelemer in Chronic HIV-Related Diarrhea Evaluated

By

New findings announced from a supplemental analysis of Mytesi (crofelemer) in patients with HIV-related diarrhea.

Child Maintains HIV Remission Without ART Since 2008

Child Maintains HIV Remission Without ART Since 2008

By

A child who was diagnosed with HIV at 1 month and received early treatment has suppressed the virus without anti-HIV therapy for 8.5 years.

New WHO Guidelines for Managing Pretreatment HIV Drug Resistance

New WHO Guidelines for Managing Pretreatment HIV Drug Resistance

By

New WHO guidelines address the issue of how to manage pretreatment human immunodeficiency virus drug resistance (HIVDR) in countries where the prevalence of HIVDR is 10% or higher.

Long-Acting Injectable Antiretrovirals for HIV Effective and Safe

Long-Acting Injectable Antiretrovirals for HIV Effective and Safe

By

The combination of long-acting intramuscular cabotegravir plus rilpivirine was demonstrated to be as effective as 3-drug daily oral ART for maintaining viral suppression of HIV-1 for up to 96 weeks in the LATTE-2 phase 2b study.

Efficacy, Safety of Fixed-Dose HIV Regimen With Bictegravir Evaluated

Efficacy, Safety of Fixed-Dose HIV Regimen With Bictegravir Evaluated

By

Gilead announced results from 2 Phase 3 studies for the investigational fixed-dose HIV regimen with bictegravir and emtricitabine for the treatment of treatment-naive adults with HIV.

Sign Up for Free e-newsletters